Domenico Santoro
Overview
Explore the profile of Domenico Santoro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
409
Citations
3847
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sciascia S, Bonelli G, Calatroni M, LImperio V, Fenoglio R, Argolini L, et al.
Minerva Urol Nephrol
. 2025 Mar;
PMID: 40052259
No abstract available.
2.
Villalobos W, Ferreira T, Borek F, Santoro D, Ferrer L, Farias M
Vet Dermatol
. 2025 Mar;
PMID: 40042058
Background: Canine atopic dermatitis (cAD) is a chronic, inflammatory, multifactorial and pruritic disease. The presence of skin barrier impairment (e.g. filaggrin alterations), along with abnormal immune responses, can negatively impact...
3.
Tikariha L, Manoli K, Lawryshyn Y, Norton J, da Silva A, Bell K, et al.
J Environ Manage
. 2025 Mar;
378:124711.
PMID: 40037245
Chlorine-based disinfectants are often used to achieve the required microbiological effluent limits and to ensure appropriate public health protection against waterborne pathogens; however, they can produce potentially harmful disinfection by-products...
4.
Chirico V, Silipigni L, Tripodi F, Conti G, Rulli I, Granata F, et al.
Pediatr Nephrol
. 2025 Mar;
PMID: 40029412
Diffuse alveolar hemorrhage and acute glomerulonephritis characterize pulmonary-renal syndrome, in which anti-glomerular basement membrane antibodies (anti-GBM) and anti-neutrophil cytoplasmic antibodies (ANCA) are often assessed. The treatment is complex, requiring a...
5.
Maressa V, Farina A, Cernaro V, Gembillo G, Longhitano E, Taverna G, et al.
G Ital Nefrol
. 2025 Mar;
42(1).
PMID: 40026221
Treating hyperkalemia is one of the main goals of supportive care in patients on hemodialysis. In this context, therapy with new potassium binders is a promising resource. The main aim...
6.
Gil N, Santoro D, Marsella R
Am J Vet Res
. 2025 Feb;
:1-6.
PMID: 40014931
Objective: To determine the in vitro activity of the low-level laser (light) therapy (LLLT) device (Phovia; Vetoquinol) on Malassezia pachydermatis. Methods: Clinical isolates of M pachydermatis (n = 30) and...
7.
Messina R, Calabrese V, Zirino F, Lipari A, Giuffrida A, Sessa C, et al.
G Ital Nefrol
. 2025 Feb;
41(6).
PMID: 39931970
The KDOQI guidelines (Kidney Disease Outcomes Quality Initiative) recommend autologous arteriovenous fistula (AVF) as the primary vascular access in hemodialysis patients because of the higher quality of life and lower...
8.
Calabrese V, Gembillo G, Longhitano E, La Placa C, Ferio C, Cernaro V, et al.
G Ital Nefrol
. 2025 Feb;
41(6).
PMID: 39931968
Complications of chronic kidney disease include endocrine and metabolic abnormalities, anaemia and a wide range of disorders of homeostasis. Our study aims to better determine the role of CKD stage...
9.
Bonelli G, Sciascia S, Calatroni M, LImperio V, Fenoglio R, Argolini L, et al.
J Nephrol
. 2025 Jan;
PMID: 39883361
Background: In an Italian cohort of lupus podocytopathy patients, we aimed to characterize the presenting features, therapy, and outcomes, and explore differences between relapsing and non-relapsing patients. Methods: We identified...
10.
Siligato R, Gembillo G, De Giorgi A, Di Maria A, Scichilone L, Capone M, et al.
Int J Nephrol Renovasc Dis
. 2025 Jan;
18:13-25.
PMID: 39872022
Purpose: Social determinants of health have been related with kidney diseases and their outcomes. Financial toxicity (FT) refers to the negative impact of health care costs on clinical conditions. This...